arrest (0.6% vs 0.2%), and MACEs (4.9% vs 3.3%) compared with nonanemic patients (all P < .001). On multivariable analysis, anemic patients had 30% increased odds of MACEs independent of procedure type (adjusted odds ratio, 1.30; 95% confidence interval [CI], 1.11-1.54; P < .01; Fig) . No significant interactions were identified between anemia and procedure type and preoperative medical comorbidities, suggesting an independent association. For each percentage point decrease of hematocrit from the normal range (39% in men and 36% in women), there was a 3.2% increase in the adjusted risk 30-day mortality (95% CI, 1.4%-5.1%; P ¼ .01) and 1.2% increase in the adjusted risk of MACE (95% CI, 0.2%-2.2%; P ¼ .02). Analysis of the two exactly matched groups (each including 2654 patients) showed even higher MACE risk in the anemic patients (adjusted odds ratio, 1.47; 95% CI, 1.15-1.90; P < .01).
IP251.
Intravenous Anti-inflammatory Agent Reduces Mortality and Morbidity After Open Abdominal Aortic Aneurysm Repair Objective: The role of nonsteroidal anti-inflammatory drugs (NSAIDs) in aortic aneurysm disease progression and prognosis has been debated because of their effect on the inflammatory pathways attributed to abdominal aortic aneurysm (AAA) disease. Animal studies demonstrated that intrathecal ketorolac (Toradol) reduces the inflammatory response associated with aortic clamping, a classic ischemiareperfusion injury example. However, no study of human patients evaluated this association. Therefore, we sought to explore the effects of ketorolac use in open AAA repair (OAR) on mortality and complications. Outcomes were in-hospital mortality and neurologic, renal, respiratory, cardiac, and hemorrhagic complications. Multivariable logistic regression analysis was implemented adjusting for age, sex, hypertension, chronic kidney disease, coronary artery disease, elective repair, congestive heart failure, aspirin, statin, beta blockers, oral NSAID use, history of musculoskeletal conditions, and Charlson Comorbidity Index, chosen on the basis of Akaike information criterion statistic and clinical relevance. We then performed coarsened exact matching at many-to-one and one-to-one options, followed by conditional regression modeling.
Results: There were 6394 patients identified (ketorolac, 806 [12.6%] Those findings were replicated through the coarsened exact matching analysis (Fig) .
Conclusions: This is the first study to demonstrate 40% reduction in mortality with intravenous ketorolac after OAR. The survival benefit could be due to its anti-inflammatory and opioid-sparing properties. This is evident by its protective effect against respiratory adverse outcomes, which are mostly linked to narcotic drugs. The renal protection could be related to reduction of the inflammatory response during clamping and unclamping. The lack of association with expected adverse cardiac or hemorrhagic effects of NSAIDs could be a result of the lower frequency as opposed to the chronic use of NSAIDs. We encourage use of ketorolac for analgesia more liberally in appropriately selected patients undergoing OAR, considering its safety and potentially protective effect.
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